A cell biological perspective on mitochondrial dysfunction in Parkinson disease and other neurodegenerative diseases

Wim Mandemakers, Vanessa A. Morais and Bart De Strooper*

Center for Human Genetics, K.U.Leuven and Department of Molecular and Developmental Genetics, VIB, Herestraat 49, 3000 Leuven, Belgium

*Author for correspondence (e-mail: Bart.destrooper@med.kuleuven.be)

Accepted 13 March 2007
Journal of Cell Science 120, 1707-1716 Published by The Company of Biologists 2007
doi:10.1242/jcs.03443

Summary
Dysfunction of mitochondria is frequently proposed to be involved in neurodegenerative disease. Deficiencies in energy supply, free radical generation, Ca\(^{2+}\) buffering or control of apoptosis, could all theoretically contribute to progressive decline of the central nervous system. Parkinson disease illustrates how mutations in very different genes finally impinge directly or indirectly on mitochondrial function, causing subtle but finally fatal dysfunction of dopaminergic neurons. Neurons in general appear more sensitive than other cells to mutations in genes encoding mitochondrial proteins. Particularly interesting are mutations in genes such as Opa1, Mfn1 and Dnm1l, whose products are involved in the dynamic morphological alterations and subcellular trafficking of mitochondria. These indicate that mitochondrial dynamics are especially important for the long-term maintenance of the nervous system. The emerging evidence clearly demonstrates the crucial role of specific mitochondrial functions in maintaining neuronal circuit integrity.

Key words: Neurodegenerative, Mitochondria, Oxidative stress, Parkinson disease, OXPHOS, Apoptosis, Mitochondrial dynamics

Introduction
Neurodegenerative diseases are characterized by the progressive death of neurons and result in memory loss, movement problems, cognitive deficits, emotional alterations and behavioral problems. Environmental factors (toxins), genetic mutations in a variety of genes, and finally, and most importantly, old age, are the major risk factors. Disease-linked mutations in genes provide key clues to the molecular mechanisms involved in the pathology and have therefore been studied intensively over the last decades (Table 1). Here, we focus on mutations causing Parkinson disease (PD). The study of these mutations and of mutations causing other diseases indicates that mitochondrial dysfunction is an important contributor to neurodegenerative processes.

PD is a chronically progressive, age-related neurodegenerative disease characterized by progressive resting tremor, rigidity, bradykinesia, gait disturbance, postural instability and dementia. A major neuro-pathological feature is the degeneration of dopamine neurons in the substantia nigra pars compacta (SNc) and in other brainstem regions. The loss of inhibitory dopaminergic innervation causes over-activity of the subthalamic nucleus and the globus pallidus, which causes the movement symptoms (Obeso et al., 2000). Lewy bodies are a second neuropathologic feature of PD. These are cosinophilic cellular inclusions comprising a dense core of filamentous material surrounded by a halo of fibrils, which mainly consists of α-synuclein (see below) (Cookson, 2005).

Several hypotheses for the progressive and selective neurodegeneration in PD have been proposed. Mitochondrial dysfunction, however, has been linked with PD for a long time. In the early 1980s, a group of young designer-drug abusers showed PD-like symptoms upon exposure to MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine), a synthetic by-product of heroin production (Langston et al., 1983). The active metabolite of MPTP, MPP\(^{+}\), selectively enters dopaminergic neurons via the dopamine transporter and potently inhibits mitochondrial complex I (Vila and Przedborski, 2003). This results in increased oxidative stress, intracellular Ca\(^{2+}\) levels and excitotoxicity, and decreased energy production, eventually culminating in neuronal damage and death. Exposure to rotenone, another complex I inhibitor, produces a similar phenotype in rodents (Betarbet et al., 2000; Manning-Bog et al., 2002; Sherer et al., 2003). Furthermore, particular mitochondrial DNA (mtDNA) polymorphisms and haplotypes are associated with risk of PD (Autere et al., 2004; Pyle et al., 2005; van der Walt et al., 2003), and mutations in mtDNA or in the nuclear-encoded mtDNA polymerase-G (POLG) cause PD-like symptoms (Luoma et al., 2004). Finally, dopaminergic neurons in the SNc are particularly sensitive to somatic mtDNA mutations, and accumulation of these is greater in PD patients compared with age-matched controls (Bender et al., 2006; Kraysberg et al., 2006). A critical threshold of approximately 60% mutated mtDNA molecules must be reached to cause dopaminergic neuronal cell death (Rossignol et al., 2003). The remaining unaffected mtDNA molecules cannot produce sufficient quantities of proteins such as cytochrome c oxidase (COX), and the respiratory chain becomes deficient.

Recently, several rare forms of inherited PD have been recognized (Polymeropoulos et al., 1997). The identification of the genes mutated has provided a major boost in our understanding of the molecular mechanism(s) causing PD...
disease. Below, we briefly summarize the salient features of the proteins encoded by these genes [SNCA (encoding α-synuclein), PARK2 (encoding parkin) PARK7 (encoding PARK7; also known and hereafter referred to as DJ-1), PINK1 (encoding the PTEN induced putative kinase 1 PINK1) and LRRK2 (encoding the leucine-rich repeat kinase 2 LRRK2)] and then focus on the evidence that mutations in these genes impinge on mitochondrial function.

**α-Synuclein**

α-Synuclein (Fig. 1A) is a natively unfolded protein that upon binding to lipid can form oligomeric or amyloidogenic filaments. Fibrillar forms of α-synuclein are the major structural component of Lewy bodies, providing compelling evidence that it plays a major role in the pathogenesis of PD (Spillantini et al., 1998). Missense mutations in α-synuclein (A30P, E46K, A53T), and gene duplications and triplications have been identified in familial cases of PD (reviewed in Savitt et al., 2006). α-Synuclein is localized predominantly in synaptic terminals and in the cytosol. Although its normal function is not quite clear, studies in zebra finch indicate a potential role in synaptic plasticity (George et al., 1995). More, but inconsistent, information on the role of α-synuclein at synapses has come from studies in mice lacking α-synuclein or both α-synuclein and β-synuclein. Although one study demonstrated dramatic loss of synaptic reserve vesicles and an increase in synaptic depression in α-synuclein-null mice (Snca<sup>am1/Snom</sup>) (Cabin et al., 2002), two other studies only showed mild (Snca<sup>am1/Ros</sup>) (Abeliovich et al., 2000) or no effects on these parameters Snca<sup>am1</sup>Sud (Schluter et al., 2003). Also, mice lacking both α-synuclein and β-synuclein (Snca<sup>am1Sud</sup>, Sncb<sup>md1Sud</sup>) show no defects in synaptic plasticity and synaptic vesicle cycling. These mice, however, do show a 20% reduction in brain dopamine levels, which is not observed in single-knockout mice and points towards functional redundancy between these proteins (Chandra et al., 2004). Because of these controversial data, the normal function of α-synuclein remains debated, although a role in synaptic integrity seems likely. Indeed, loss of α-synuclein accelerates degeneration of presynaptic terminals in mice lacking Dnajc5 (Dnajc<sup>gim1Sud</sup>), encoding the chaperone protein cystein-string protein α (CSPα). Thus, Snca and Dnajc5 are in a genetic pathway important for the integrity of synaptic nerve terminals (Chandra et al., 2005).

Transgenic mouse models overexpressing wild-type or mutant forms of α-synuclein display disappointingly few symptoms relevant to PD (reviewed in Fleming et al., 2005). However, these mice do show an increased vulnerability of SNc neurons to MPTP (Fleming et al., 2005). Overexpression of α-synuclein in Drosophila melanogaster results in adult-onset loss of dopaminergic neurons, the appearance of filamentous intraneuronal inclusions containing α-synuclein and locomotory dysfunction. This model closely recapitulates the essential features of the human disorder (Bilen and Bonini, 2005; Feany and Bender, 2000). It is still unclear how mutant or overexpressed α-synuclein can lead to neuronal cell death. SNCA overexpression might block ER-Golgi trafficking (Cooper et al., 2006) by sequestering vesicle-trafficking proteins, such as Ypt1p, and interfering with its function. Conversely, overexpression of these, in particular Ypt1p and its ortholog Rab1, can attenuate α-synuclein-induced toxicity. Similar pathological mechanisms might be involved in synaptic vesicle transport (Cooper et al., 2006). For instance the scaffolding protein septin 4 (Sept4) frequently co-aggregates with α-synuclein in Lewy bodies in PD and is often deficient in dopaminergic nerve terminals in the striatum (Ihara et al., 2003; Ihara et al., 2007). α-Synuclein appears to interact with Sept4, and dopaminergic neurons deficient in Sept4 become more susceptible to further dysfunction and degeneration in PD (Ihara et al., 2007). Sept4-knockout mice (Sept4<sup>am1Ksh</sup>) display decreased dopamine release (Ihara et al., 2007). Ihara et al., therefore propose that Sept4 and α-synuclein are components of presynaptic complexes at the dopaminergic terminals, and that lack of the physiological association with Sept4 facilitates self-aggregation of α-synuclein.

**Specific sensitivity of dopaminergic neurons to mitochondrial stress**

Why are dopaminergic neurons so sensitive to α-synuclein toxicity? Dopamine is inherently unstable and can generate reactive oxygen species (ROS) and, via monoamine oxidase (MAO), H<sub>2</sub>O<sub>2</sub> (Lotharius et al., 2002). Dopamine is synthesized in the cytosol and rapidly pumped by vesicular monoamine transporter 2 (VMAT2, also known as SLC18A2) into synaptic vesicles, where the low vesicular pH and the absence of MAO limit its breakdown. Defects in the early secretory pathway could cause a shortage of synaptic vesicles and reduce delivery of VMAT2 to the synapse. This would impede dopamine loading and increase cytosolic dopamine levels and consequently ROS production. Although dopamine itself may not be toxic, dopamine metabolites play a role in α-synuclein aggregation (Galvin, 2006) and dopamine-α-synuclein adducts stabilize α-synuclein protofibrils (Conway et al., 2001).

Although there is no evidence for mitochondrial localization of α-synuclein, overexpression of mutant α-synuclein sensitizes neurons to oxidative stress and damage by dopamine metabolites and mitochondrial toxins such as MPP<sup>+</sup> and 6-hydroxydopamine, resulting in increased protein carbonylation and lipid peroxidation in vitro and in vivo (Orth et al., 2003). Interestingly, α-synuclein-knockout mice (Snca<sup>am1Wld</sup>, Snca<sup>am1Sud</sup>, (Snca<sup>am1</sup>Ros)) mice have marked resistance to MPTP and other mitochondrial toxins, such as malonate and 3-nitropropionic acid (Dauer et al., 2002; Fornai et al., 2005; Klivenyi et al., 2006). α-Synuclein deficiency seems to result in a reduction of oxidative stress and, in addition, it has been proposed that α-synuclein oligomers generate pore-like structures (Lashuel et al., 2002), which might disrupt the membranes of organelles such as mitochondria.

**Parkin**

Homozygous mutations in parkin (Fig. 1B) (Kitada et al., 1998) account for about half of all cases of autosomal recessive PD (ARPD) (Abbas et al., 1999; Lucking et al., 2000). A few dominant mutations have also been described (West and Maidment, 2004). Parkin functions as an E3 ubiquitin ligase (Shimura et al., 2000) catalyzing the ubiquitylation of damaged proteins, which leads to their degradation by the 26S proteasome (Ciechanover, 1998). Thus, mutations in parkin should impact on the unfolded protein stress response, resulting in accumulation of one or more of its presumed
Mitochondrial disfunction in neurodegenerative disease

Fig. 1. Models of human PD-associated proteins. (A) α-Synuclein is a 140 amino acid protein belonging to a family of related synucleins that includes β- and γ-synuclein. It has an N-terminal amphipathic region containing six imperfect repeats with a KTKEGV consensus sequence, a hydrophobic central region that contains the non-amyloid-β component (NAC) domain, and a highly acidic C-terminal tail containing several phosphorylation sites. (B) Parkin is a 465 amino acid protein that functions as an E3 ubiquitin ligase. It contains an N-terminal ubiquitin-like (UBL) domain that binds to RPN10 subunit of the 26S proteasome system, a central linker region, and a C-terminal RING domain comprising two RING finger motifs (RING1 and RING2) separated by an in-between-RING (IBR) domain. (C) DJ-1 is a highly conserved 189 amino acid protein that is ubiquitously and abundantly expressed in most mammalian tissues and belongs to the DJ-1/Thi3/Pfpl superfamily. (D) PINK1 is a highly conserved 581 amino acid protein that is ubiquitously expressed. It localizes to the mitochondria via an N-terminal mitochondrion-targeting motif (MTS). Furthermore, it shares sequence similarity with Ca2+/calmodulin-dependent protein kinase I and contains a catalytic serine/threonine kinase domain. (E) LRRK2 is a 2537 amino acid complex multi-domain protein that consists of an ankyrin-repeat region (ANK), an N-terminal leucine-rich repeat domain (LRR), a GTPase Roc domain (Roc) followed by an associated C-terminal of Roc (COR), a mitogen-activated kinase kinase kinase domain, and a C-terminal WD40 repeat (approximately 40 amino acid repeats that form a β-propeller structure that might serve as a rigid scaffold for protein interactions). Approximate positions of missense mutations causing PD are indicated with arrows.

substrates and consequent death of neurons in the SNc (reviewed in Cookson, 2005). In general, no Lewy bodies are observed (Farrer et al., 2001; Mori et al., 1998; Sasaki et al., 2003). Remarkably, reduced expression of several enhancers of fly death (Greene et al., 2005). GSTS1 is an antioxidant and flies lacking the genes encoding GSTS1 display progressive degeneration of dopaminergic neurons and increased oxidative damage (Greene et al., 2005). A genomic screen in the park2 flies identified loss-of-function of glutathione S-transferase (GstS1) as one of the strongest enhancers of fly death (Greene et al., 2005). GSTS1 is an important antioxidant and flies lacking the genes encoding both parkin and GSTS1 display progressive degeneration of dopaminergic neurons and increased oxidative damage (Whitworth et al., 2005). Loss of parkin in mice (Park2m1shm) results in increased dopamine levels and reduced synaptic excitability in the striatum, and behavioral defects (Goldberg et al., 2003). Remarkably, reduced expression of several proteins involved in mitochondrial function and oxidative stress, including subunits of complexes I and IV, is observed as well (Palacino et al., 2004). Mitochondria isolated from the striatum of Park2m1shm mice have decreased mitochondrial respiratory capacity and show evidence of increased formation of lipid by-products of ROS, such as protein carbonyls and lipid peroxides (Palacino et al., 2004). Intriguingly, parkin deficiency alone is not sufficient to cause neurodegeneration, which suggests additional unknown triggers are important for the disease process (Goldberg et al., 2003; Itier et al., 2003; Perez and Palmiter, 2005).

The mechanism by which parkin might regulate mitochondrial function remains unclear. Loss-of-function of this E3 ligase might lead to accumulation of oxidatively damaged proteins. Various putative parkin substrates, such as CDCrel-1/Sept5, CDCrel-2/Sept4, Pael-R, cyclin E, synphilin-1, p38/JTV1 and FB1, accumulate in parkin-associated PD, whereas only p38/JTV1 and FB1 also accumulate in sporadic PD and parkin knockout (Park2m1Tmd) mice, which suggests these might be genuine parkin substrates (reviewed in Moore et al., 2005a). None of these is localized to mitochondria, and their accumulation might only indirectly affect mitochondrial function. However, recently parkin has been shown to ubiquitylate the PD-associated protein LRRK2 (see below), which in turn activates auto-ubiquitylation of parkin (Smith et al., 2005). Interestingly, West and co-workers have shown that approximately 10% is localized to the mitochondrial outer membrane (West et al., 2005). Parkin itself is sensitive to oxidative stress: dopamine-quinone and s-nitrosylation covalently modify it and inactivate its E3 ligase activity.
Fig. 2. Schematic representation of mitochondrial fusion and fission events. During fusion mitofusin 1 or 2 (Mfn1/2) proteins link two juxtaposed mitochondria through their coiled-coil domains. This is followed by outer, and subsequently inner, membrane fusion, which is GTP dependent and regulated by Opa1. During fission, Dnm1 is recruited from the cytosol to the outer mitochondrial membrane, where it interacts directly or indirectly with Fis1, leading to constriction of mitochondria and sequential separation of the inner and outer membrane.

DJ-1
Mutations in the gene encoding DJ-1, which encodes a putative sensor of oxidative stress, are rare causes of PD. DJ-1 (Chung et al., 2004; LaVoie et al., 2005). This suggests the possibility of a feedback loop and a more general mechanism for parkin dysfunction in the pathogenesis of sporadic PD. A genetic interaction between parkin and the mitochondrial kinase Pink1 in D. melanogaster (see below) provides further evidence for parkin deficiency playing a general role in PD via mitochondria (Clark et al., 2006; Park et al., 2006; Yang et al., 2006). Recent data also show that parkin and Pink1 might physically interact (Moore, 2006). Although the mitochondrial localization of Pink1 is clear (see below), it is still debated whether parkin is associated with mitochondria.

PINK1
Homozygous or compound heterozygous mutations in the PINK1 gene (Fig. 1D) cause forms of PD that display a wide phenotypic spectrum, from early onset with atypical features to late-onset PD with symptoms similar to those in sporadic cases (Hatanou et al., 2004; Valente et al., 2004a; Valente et al., 2004b). PINK1 is an ubiquitously expressed kinase (Silvestri et al., 2005; Valente et al., 2004a). It tends to be poorly soluble and has a propensity to aggregate, which might explain its presence in 10% of Lewy bodies in sporadic PD (Gandhi et al., 2006). Overexpression of the gene encoding PINK1 promotes its interaction with parkin, linking DJ-1 and parkin in a common pathway (Moore et al., 2005b). Thus, DJ-1 may play a crucial role both sensing and conferring protection against a range of oxidative stressors, using different mechanisms. Flies and mice deficient in the gene encoding DJ-1 are indeed more susceptible to oxidative toxins (Kim et al., 2005; Menzies et al., 2005; Meulener et al., 2005; Park et al., 2005; Yang et al., 2005). Circumstantial evidence thus strongly indicates that DJ-1 directly or indirectly protects against mitochondrial dysfunction.
Mitochondrial disfunction in neurodegenerative disease

further argues for a common mitochondrial pathway in PD (Clark et al., 2006; Park et al., 2006; Yang et al., 2006). Parkin can restore normal mitochondrial morphology, DNA and protein content, but does not rescue the sensitivity of PINK1 mutant flies to stress-induced apoptosis. This suggests that PINK1 acts upstream of parkin to protect mitochondrial integrity (Clark et al., 2006; Park et al., 2006; Yang et al., 2006). PINK1 is the only PD-associated protein that clearly localizes to mitochondria and might be crucial for our understanding of the contribution of mitochondrial dysfunction to PD.

**LRRK2**

Mutations in the LRRK2 gene, especially LRRK2 G2019S (Fig. 1E), are very common in familial forms of PD but also in sporadic PD. In the latter, the absence of a family history suggests reduced penetrance or a de novo occurrence of the mutation (Di Fonzo et al., 2005; Kachergus et al., 2005; Nichols et al., 2005). The G2019S mutation has indeed variable penetrance, reaching 17% at 50 years and 85% at 70 years, a profile that mimics the occurrence of idiopathic sporadic PD. Little is known about LRRK2 function. It is a multidomain protein that has both a kinase and GTPase domain (Fig. 1E) (Gloeckner et al., 2006; West et al., 2005). Significantly, three PD-associated mutations, two in the kinase domain (G2019S and I2020T) and one in the Ras of complex/C-terminal of Roc (ROC/COR) GTPase domain (Bosgraaf and Van Haastert, 2003) (R1441C), increase LRRK2 autophosphorylation, hinting at a dominant gain-of-function mechanism in PD (Gloeckner et al., 2006; West et al., 2005; West et al., 2007). Indeed, over-expression of R1441C, Y1699C or G2019S LRRK2 can induce neuronal degeneration in mouse primary cortical neurons (Greggio et al., 2006; Smith et al., 2006; Smith et al., 2005). Interestingly, PD-associated LRRK2 mutations that enhance kinase activity induce a progressive reduction in neurite length and branching in neurons in vitro and in vivo, which is reversed by loss of LRRK2 (MacLeod et al., 2006).

Neurons that express PD-associated LRRK2 mutations also display prominent phospho-tau-positive inclusions that colocalize with the lysosomal marker LAMP1. The neurons ultimately undergo apoptosis (MacLeod et al., 2006). It is known that hyperphosphorylation of tau leads to aggregate formation and axonal/neuronal degeneration in many neurodegenerative diseases (reviewed in Lee et al., 2001). Tau might be a molecular target for LRRK2 kinase activity, because the two proteins colocalize in inclusions. However, Macleod et al. have failed to detect evidence of direct phosphorylation of tau by LRRK2 in vitro and favor a model in which LRRK2 indirectly modifies tau through modulation of the activity of other kinases or phosphatases previously implicated in tau phosphorylation, such as GSK3β (Lee et al., 2001). Additional studies will be necessary to pinpoint the action of LRRK2 in these signaling cascades.

Confocal studies in primary cortical neurons and ultrastructural analysis in rodent basal ganglia detect LRRK2 in association with membranous and vesicular structures such as lysosomes, endosomes, transport vesicles and mitochondria (Biskup et al., 2006; West et al., 2005). Subcellular fractionation confirms that approximately 10% of total LRRK2 is associated with the mitochondrial outer membrane in rodent brain (Biskup et al., 2006; West et al., 2005). LRRK2 might therefore have a role in mitochondrial physiology, although this remains speculation.

**Mitochondrial dynamics and neuronal dysfunction**

As discussed above, the inherent stress imposed upon dopaminergic neurons by dopamine metabolism could explain the particular sensitivity of these particular neurons to mitochondrial dysfunction. Other neurons, however, are also sensitive to mitochondrial dysfunction (see Table 1). Mitochondria are remarkably dynamic organelles that undergo continual cycles of fusion and fission (Fig. 2). Strikingly, several proteins that are encoded by genes mutated in neurodegenerative diseases are involved in mitochondrial dynamics, which suggests that this is particularly important for the integrity of the nervous system. Fusion and fission events mix membranes and contents, but are also likely to be involved in control of the subcellular localization of mitochondria. Dramatic changes in morphology are also observed during apoptosis. The balance between fusion and fission thus determines not only the overall morphology of mitochondria in cells but has also important consequences for mitochondrial function (reviewed in Chan, 2006). Given the complex topology and energy needs of the nervous system, it is not so surprising that defects in mitochondrial dynamics lead to neurological disease.

Mutations in human mitofusin-2 (Mfn2) cause Charcot-Marie-Tooth disease (Zuchner et al., 2004). Mitofusins Mfn1 and Mfn2 are essential GTPases localized to the mitochondrial outer membrane. Both proteins form complexes in trans that tether mitochondria together, promoting mitochondrial fusion (Chen et al., 2003; Koshiba et al., 2004). Deletion of Mfn1 or Mfn2 results in mitochondrial fragmentation due to unbalanced fission (Chen et al., 2005; Koshiba et al., 2004). Optic atrophy 1 (OPA1) is another example of a protein involved in mitochondrial dynamics. Mutations in its gene are the major cause of genetic forms of blindness (Delettre et al., 2000). OPA1 is a dynamin-related GTPase and localizes to the intermembrane space of mitochondria, where it is tightly associated with the inner membrane (Cereghetti and Scorrano, 2006; Chan, 2006; Olichon et al., 2002). Interestingly, Opa1 interacts genetically with Mfn1, which suggests it coordinates the fusion reactions of outer and inner membranes (Cipolat et al., 2004).

These proteins also affect the subcellular localization of mitochondria. Overexpression of Mfn1 in primary cultures of neurons results in decreased localization of mitochondria to dendritic spines, whereas overexpression of dynamin-1-like (Dnm11, also known as Drp1), a protein involved in mitochondrial fission (see below), results in re-localization of mitochondria to the spines (Li et al., 2004). Remarkably, mitochondrial and synaptic activities influence each other: repetitive depolarization results in fusion of mitochondria and their relocation to the spines.

Mitochondria are particularly abundant at the other sites of synapses: axons and synaptic terminals. They are probably needed there to provide the enormous amounts of ATP associated with the transmission of axon potentials. Loss-of-function mutations in the D. melanogaster genes encoding the coiled-coil protein Milton (Stowers et al., 2002) or the Rho-related GTPase Miro (Guo et al., 2005), which are both involved in transport of mitochondria along microtubules, lead to severe phenotypes characterized by partial or complete loss
Interestingly, OIP106 is mutated in hypertonic mice, which show motor pathway defects in the central nervous system (Gilbert et al., 2006).

### Table 1. Mutated proteins that lead to neurodegenerative disorders

| Protein       | Disease                          | Function                                                                 | References                  |
|---------------|----------------------------------|---------------------------------------------------------------------------|-----------------------------|
| A Mutant proteins with primary mitochondrial localization |                                |                                                                           |                             |
| PANK2         | Brain iron accumulation (NBIA)   | Mitochondrial kinase involved in the biosynthesis of coenzyme A, an essential enzyme for energy metabolism, fatty acid synthesis and degradation, neurotransmitter and glutathione metabolism reviewed in Hayflick, 2003 |
| MFN2          | Charcot-Marie-Tooth type 2A      | Mitochondrial outer membrane GTase that is involved in mitochondrial dynamics/fusion Kijima et al., 2005 |
| GDAP1         | Charcot-Marie-Tooth type 4A      | Mitochondrial outer membrane protein probably involved in fusion and cristae dynamics Niemann et al., 2005 |
| Fmytatin (FXN) | Friedreich ataxia                | Involved in the home biosynthesis, formation of iron-sulfur clusters and iron detoxification in mitochondria reviewed in Bence et al., 2006 |
| Paraplegin (SPG7) | Hereditary spastic paraplegia |Mitochondrial inner-membrane metaloprotein involved in assembly of the respiratory chain complexes reviewed in Rugarli and Langer, 2006 |
| HSP60 (SPG13) | Hereditary spastic paraplegia    | Mitochondrial chaperone involved in protein folding reviewed in Rugarli and Langer, 2006 |
| OPA1          | Dominant optic atrophy           | Mitochondrial inner membrane dynamin-related GTase involved in maintaining cristae integrity and mediating mitochondrial fusion reviewed in Olichon et al., 2006 |
| OPA3          | Recessive optic atrophy          | Mitochondrial protein with unknown function Votmale, 2004 |
| ATPase6       | Neurpathy ataxia and retinitis pigmentosa | Component of the ATP synthase of the mitochondrial respiratory chain involved in the assembly of the F,Fe complex Cortes-Hernandez et al., 2007 |
| OMU/HTRA2     | Associated with Parkinson disease | Mitochondrial intermembrane space serine protease which is released into the cytosol upon pro-apoptotic stimuli Strauss et al., 2005 |
| PINK1         | Parkinson disease                | Mitochondrial serine/threonine kinase that appears to be critical to prevent oxidative stress Peit et al., 2005; Valente et al., 2004 |

| B Mutant proteins potentially affecting mitochondrial function |                                |                                                                           |                             |
|---------------|----------------------------------|                                                                           |                             |
| SOD1          | Amyotrophic lateral sclerosis    | Superoxide dismutase that partially localizes to the mitochondrial intermembrane space matrix, where the mutant form possibly interacts with mitochondrial chaperone proteins affecting mitochondrial protein import Li et al., 2004 |
| Hunitin via PGC-1α and p53 | Huntington disease | Cytoplasmic protein whose function remains unclear. However, mutant Huntington influences transcriptional activity of p53 and PGC-1α Bae et al., 2005; Cui et al., 2006 |
| DJ-1          | Parkinson disease                | Partially localizes to the mitochondrial intermembrane space and matrix, and acts as a redox sensor protecting against cell death especially induced by oxidative stress Canet-Aviles et al., 2004 |
| LRRK2         | Parkinson disease                | Kinase that partially associates with the outer mitochondrial membrane reviewed in Mau et al., 2006 |
| Parkin        | Parkinson disease                | Ubiquitin E3 ligase that partially associates with the outer mitochondrial membrane where it has been shown to protect against mitochondrial swelling and cytochrome c release Darios et al., 2003 |

of neurotransmission. In a genetic screen for modifiers of synaptic neurotransmission, Verstreken et al. (Verstreken et al., 2005) identified the D. melanogaster Dnm11 orthologue Drp1 as essential for sustained neurotransmission during rapid stimulation. Drp1 deficiency results in synaptic depletion of mitochondria, and although basic neurotransmission activity appears to be sustained, the lack of mitochondria makes it impossible to mobilize a reserve pool of neurotransmitter vesicles that is essential for rapid transmission. DNM11 is a cytoplasmic protein and needs FIS1, a mitochondrial outer membrane protein, to induce fission of mitochondria (Yoon et al., 2003; Yu et al., 2005). The process of fission and fusion thus depends on a complex molecular machinery, providing ample opportunities for speculation on potential roles of kinases such as LRRK2 and PINK1 in its regulation. Interestingly, the LRRK2 GTPase domain shares significant sequence similarity with the Rho GTPase domain of Miro (Guo et al., 2005). Miro and Milton directly interact and this interaction is essential for anterograde transport of mitochondria (Glatzer et al., 2006). Recently, mammalian orthologues of Milton have been identified, OIP106 and GRIF1 (also known as Trak1 and Trak2, respectively) (Brickley et al., 2005; Fransson et al., 2006). Interestingly, OIP106 is mutated in hypertonic mice, which show motor pathway defects in the central nervous system (Gilbert et al., 2006).

### Apoptosis and disturbances in energy metabolism in neurodegenerative disease

The proteins involved in mitochondrial dynamics not only are important for the subcellular distribution of these organelles in neurons but also contribute directly or indirectly to other mitochondrial functions. OPA1 illustrates this very well. Overexpression of OPA1 induces mitochondrial elongation and affects transport but also protects against apoptosis. Recently it has become clear that the two functions are part of two genetically distinct pathways (Cipolat et al., 2004; Cipolat et al., 2006). Mitochondrial elongation requires membrane-bound OPA1 and depends on MFN1, but not MFN2, whereas the anti-apoptotic function of OPA1 requires a soluble form of OPA1 that is generated by the mitochondrial rhomboid protease PARL. This soluble form of OPA1 is loosely bound to the inner membrane, apparently partially in complex with membrane-bound forms of OPA1, forming a multimeric complex that regulates the tightness of mitochondrial cristae junctions and therefore cytochrome c release during apoptosis (Cipolat et al., 2006; Frezza et al., 2006).
Mitochondrial fission is similarly closely associated with the apoptosis pathway: mitochondrial fragmentation occurs early in apoptosis, and inhibition of DNMT1 or FIS1 can protect against cell death (Frank et al., 2001; Lee et al., 2004). Increased rates of apoptosis could theoretically contribute to neurodegeneration, although the evidence for apoptosis in human brain material remains controversial (Dauer and Przedborski, 2003).

It is not clear to what extent fusion and fission contribute to the maintenance of the oxidative phosphorylation (OXPHOS) pathway. The mixing of DNA and protein content during fusion probably reduces the effect of accumulating mutations in mtDNA, possibly stabilizing mitochondrial performance. Again, this must be confirmed in animal model studies. Recently, Ekstrand et al. showed that the specific inactivation of mitochondrial transcription factor A (TFam) in dopaminergic neurons leads to defects in the OXPHOS pathway that result in PD-like symptoms in mice (Ekstrand et al., 2007). Evidence from studies of other genetic diseases corroborates the concept that disturbances of the OXPHOS system contribute to neurodegeneration. Mutations in frataxin (FXN) (Table 1) cause Friedreich ataxia (Wilson, 2006). Deletion of the yeast orthologue of frataxin causes accumulation of iron in the mitochondria, loss of mtDNA and impaired OXPHOS activity (Koutnikova et al., 1997; Wilson and Roof, 1997). Additional studies have demonstrated severe deficiencies in the activities of Complexes I, II and III and aconitase, and iron accumulation in tissue from Friedreich ataxia patients (Rotig et al., 1997).

Mutations in the human genes encoding HSP60 (HSPD1) and paraplegin (SPG7) (Table 1) cause hereditary spastic paraplegias. HSP60 is a mitochondrial matrix protein chaperone and plays a role in the folding and import of mitochondrial proteins (Casari et al., 1998). Paraplegin is a subunit of a mitochondrial AAA protease and is localized to the inner mitochondrial membrane (Rugarli and Langer, 2006). Patients with SPG7 mutations have compromised complex I activity and their cells display increased sensitivity to oxidative stress (Elluech et al., 2006). Apart from clearing misfolded protein, the protease is also involved in the activation of a mitochondrial ribosomal subunit (Nolden et al., 2005).

Finally, OXPHOS impairment leading to neurodegeneration can also be caused by mutations in proteins that are not or only partially localized to mitochondria and therefore probably indirectly affect mitochondrial homeostasis (Table 1). For instance, reduced activity of several key components of the OXPHOS system, including complexes II, III and IV, occurs in Huntington disease at an advanced stage of the disorder (Browne and Beal, 2004). Although the exact function of huntingtin protein remains unknown (Truant et al., 2006), mutant huntingtin binds to several key transcription factors and co-activators, such as p53 (Bae et al., 2005) and the peroxisome proliferator-activated receptor gamma coactivator 1α (PGC-1α) (Cui et al., 2006). Repression of this transcription co-activator leads to impaired mitochondrial function and enhances the pathogenesis Huntington disease (St-Pierre et al., 2006).

Conclusions and Perspectives

The evidence linking mitochondrial dysfunction to neurodegenerative disorders and, in particular, PD is impressive. It remains, however, speculation whether the mutations in the different PD genes all finally converge on a common mitochondrial pathway and whether such a pathway is also relevant for understanding of sporadic PD. The genes shown to be involved in mitochondrial dysfunction in PD and other neurodegenerative diseases provide us with a handle to approach these questions. Hopefully we will be able to lay out progressively a map of proteins and functional interactions that describes a molecular network linking the different genes and proteins to a common final pathway. An important goal, for instance, is the identification of the physiological substrates for the kinases PINK1 and LRRK2. If they are proteins relevant to mitochondrial relevant proteins we could obtain clues to whether the OXPHOS, cell death or fusion/fission pathways are part of such a final pathway. In neurodegenerative diseases other than PD, deregulation of mitochondrial dynamics seems to be a recurrent theme. Whether this is also true for PD is an intriguing possibility but has thus far remained little explored.

In vivo model systems for various neurodegenerative diseases provide a powerful tool to investigate genetic interactions and unravel a hypothetical genetic involvement in the (dys)regulation of mitochondrial function in neurodegenerative disease. In this respect, knockout and transgenic mutant mouse models of PINK1 and LRRK2 are eagerly awaited. Furthermore, it will be interesting to investigate whether proteins, such as PGC-1α, that are apparently involved in other neurodegenerative diseases are also of relevance in PD.

Finally, further work will significantly contribute to our knowledge of mitochondrial function. Challenging questions are whether mitochondria have tissue-specific features and whether one can therapeutically exploit mitochondrial function to treat neurodegenerative disease. The new genetic and cell biological studies in human and animals provide ample starting points for us to tackle these important challenges.

Research in the group of B.D.S. is supported by a Pioneer award from the Alzheimer’s Association, the Fund for Scientific Research, Flanders; K. U. Leuven (GOA); and Federal Office for Scientific Affairs, Belgium (IUAP). Wim Mandemakers is a visiting postdoctoral researcher of the FWO. V.M. is a Marie Curie Fellow of the EU.

References

Abbas, N., Lucking, C. B., Ricard, S., Durr, A., Bonifati, V., De Michele, G., Bouley, S., Vaughan, J. R., Gasser, T., Marconi, R. et al. (1999). A wide variety of mutations in the parkin gene are responsible for autosomal recessive parkinsonism in Europe. French Parkinson’s Disease Genetics Study Group and the European Consortium on Genetic Susceptibility in Parkinson’s Disease. Hum. Mol. Genet. 8. 567-574.

Abeliovich, A., Schmitz, Y., Farinas, I., Choi-Lundberg, D., Ho, W. H., Castillo, P. E., Shinys, N., Verdugo, J. M., Armanini, M., Ryan, A. et al. (2000). Mice lacking alpha-synuclein display functional deficits in the nigrostriatal dopamine system. Neuron 25. 239-252.

Autere, J., Moilanen, J. S., Finnla, S., Soininen, H., Mannermäki, A., Hartikainen, P., Hallikainen, M. and Majamäki, K. (2004). Mitochondrial DNA polymorphisms as risk factors for Parkinson’s disease and Parkinson’s disease dementia. Hum. Genet. 115. 29-35.

Bae, B. I., Xu, H., Igarashi, S., Fujimoto, M., Agrawal, N., Taya, Y., Hayward, S. D., Moran, T. H., Montell, C., Ross, C. A. et al. (2005). P53 mediates cellular dysfunction and behavioral abnormalities in Huntington’s disease. Neuron 47. 29-41.

Bhandopadhyay, R., Kingsbury, A. E., Cookson, M. R., Reid, A. R., Evans, I. M., Hope, A. D., Pittman, A. M., Lashley, T., Canet-Aviles, R., Miller, D. W. et al. (2004). The expression of DJ-1 (PARK7) in normal human CNS and idiopathic Parkinson’s disease. Brain 127. 420-430.

Benca, K. Z., Kondapalli, K. C., Cook, J. D., McMahon, S., Millan-Pacheco, C., Pastor, N. and Steenbergh, T. L. (2006). The structure and function of frataxin. Crit. Rev. Biochem. Mol. Biol. 41. 269-291.

Bender, A., Krishnan, K. J., Morris, C. M., Taylor, G. A., Reeve, A. K., Perry, R. H.,
dMIR is required for axonal transport of mitochondria to Drosophila synapses. *Neuron* **47**, 379-393.

Hatano, Y., Li, Y., Sato, K., Asakawa, S., Yamamura, Y., Tomiyama, H., Yoshino, A., Hasahina, M., Kobayashi, S., Hashin-Baer, S. et al. (2004). Novel PINK1 mutations in early-onset Parkinsonism. *Ann. Neurol.* **56**, 424-427.

Hayfield, J. C., Lobanov, P. V., Li, C., Bardin, M. A., McCarthy, E. J., Volek, J. S., Storch, L. A., Schon, E. D., Yu, K., Bachrach, L. Y. et al. (2016). Association between early-onset Parkinson’s disease and mutations in the parkin gene. *Nature Med.* **22**, 1641-1644.

Matsu, I. F., Wedemeyer, W. J., Farrer, M. J., Taylor, P. J. and Gallo, K. A. (2006). LRRK2 in Parkinson’s disease: protein domains and functional insights. *Trends Neurosci.* **29**, 286-293.

Meehan, P. M., Yenisseti, S. C. and Min, K. T. (2005). Roles of Drosophila DJ-1 in survival of dopaminergic neurons and oxidative stress. *Curr. Biol.* **15**, 1578-1582.

Meulener, M., Whitworth, A. J., Armstrong-Gold, C. E., Rizzi, P., Heutink, P., Wes, P. D., Pallance, L. J. and Bonini, N. M. (2005). Drosophila DJ-1 mutants are selectively sensitive to environmental toxins associated with Parkinson’s disease. *Curr. Biol.* **15**, 1572-1577.

Miller, D. W., Ahmad, R., Hague, S., Baptista, M. J., Canet-Aviles, R., McLendon, C., Carter, D. M., Zhu, P. P., Stadler, J., Chandran, J. et al. (2003). L166P mutant DJ-1, causative for recessive Parkinson’s disease, is degraded through the ubiquitin-proteasome system. *J. Biol. Chem.* **278**, 36588-36595.

Mitsumoto, A. and Nakagawa, Y. (2001). DJ-1 is an indicator for endogenous reactive oxygen species elicited by etodixone. *Free Radic. Res.* **35**, 885-893.

Moore, D. J. (2006). Parkin: a multifaceted ubiquitin ligase. *Biochem. Soc. Trans.* **34**, 373-377.

Moore, D. J., Zhang, L., Dawson, T. M. and Dawson, V. L. (2003). A missense mutation (L166P) in DJ-1, linked to familial Parkinson’s disease, confers reduced protein stability and impairs homo-oligomerization. *J. Neurochem.* **87**, 1558-1567.

Moore, D. J., West, A. B. and Dawson, T. M. (2007). Molecular pathophysiology of Parkinson’s disease. *Annu. Rev. Neurosci.* **28**, 57-87.

Moore, D. J., Zhang, L., Troncoso, J. C., Lee, M. K., Hattori, N., Mizuno, Y., Dawson, T. M. and Dawson, V. L. (2005b). Association of DJ-1 and parkin mediated by parkin DJ-1 mutations and oxidative stress. *Hum. Mol. Genet.* **14**, 71-84.

Mori, H., Kondo, T., Yokochi, M., Matsumine, H., Nakagawa-Hattori, Y., Miyake, T., Suda, K. and Mizuno, Y. (1998). Pathologic and biochemical studies of juvenile Parkinsonism linked to chromosome 6q. *Neurology* **51**, 890-892.

Mulchherzer, S. and Das, S. K. (2002). Molecular distribution of “peripheral type” binding sites for [3H]Ro5-4864 in guinea pig lung. Localization to the mitochondrial inner membrane. *J. Biol. Chem.* **276**, 16713-16718.

Nichols, W. C., Pankratz, N., Hernandez, D., Paison-Ruiz, C., Jain, S., Halter, C. A., Marciano, R. E., Reed, T., Rudolph, A., Shults, C. W. et al. (2005). Genetic screening for a single common LRRK2 mutation in familial Parkinson’s disease. *Lancet* **365**, 410-412.

Niemann, A., Rueegg, M., La Padula, V., Schenone, A. and Suter, U. (2005). Ganglioside-induced differentiation associated protein 1 is a regulator of the mitochondrial network: new implications for Charcot-Marie-Tooth disease. *J. Cell Biol.* **170**, 1067-1078.

Nolden, M., Ehres, S., Koppen, M., Bernacchia, A., Rugari, E. I. and Langer, T. (2005). The m-AAPa protease defective in hereditary spastic paraplegia controls ribosome assembly in mitochondria. *Cell* **123**, 277-289.

Obeso, J. A., Rodriguez-Oroz, M. C., Rodriguez, M., Lanciego, J. L., Artieda, J., Gonzalez, N. and Olanow, C. W. (2000). Pathophysiology of the basal ganglia in Parkinson’s disease. *Trends Neurosci.* **23**, 58-61.

Olichon, A., Emirone, L., Drogo, N., Pelisson, D., Brichese, L., Gas, N., Guillou, E., Delettre, C., Valette, A., Hamel, C. P. et al. (2002). The human dopamine-related protein OPAL is anchored to the mitochondrial inner membrane facing the intermembrane space. *FEBS Lett.* **523**, 176-179.

Olichon, A., Guillou, E., Delettre, C., Landes, T., Arnaune-Pelloquin, L., Emirone, L. J., Mills, V., Dalouay, M., Hamel, C., Amati-Bonneau, P. et al. (2006). Mitochondrial dysfunctions and disease. *OPAL. Biochim. Biophys. Acta* **1765**, 500-509.

Ollmann, L., Brown, W., Wilkinson, K. D., Rees, H. D., Huai, Q., Ke, H., Levey, A. I. and Chin, L. S. (2004). Familial Parkinson’s disease-associated L166P mutation disrupts DJ-1 protein folding and function. *J. Biol. Chem.* **279**, 8506-8515.

Orth, M., Tabrizi, S. J., Schapira, A. H. and Cooper, J. M. (2003). Alpha-synuclein expression in HEK293 cells enhances the mitochondrial sensitivity to rotenone. *Neurosci. Lett.* **351**, 29-32.

Palacino, J. J., Bajj, D., Goldberg, M. S., Krauss, S., Motz, C., Wacker, M., Klose, J. and Shen, J. (2004). Mitochondrial dysfunction and oxidative damage in parkin-deficient mice. *J. Biol. Chem.* **279**, 18614-18622.

Park, J. K., Kim, S. Y., Cha, G. H., Lee, S. B., Kim, S. and Chung, J. (2003). Drosophila DJ-1 mutants show oxidative stress-sensitive locomotive function. *Gene* **361**, 133-139.

Park, J. K., Lee, S. B., Lee, S. K., Kim, Y., Song, S., Kim, S., Bae, E., Kim, J., Shong, M., Kim, J. M. et al. (2006). Mitochondrial dysfunction in Drosophila PINK1 mutants is complemented by parkin. *Nature* **441**, 1157-1161.

Perez, F. A. and Palmiter, R. D. (2005). Parkin-deficient mice are not a robust model of parkinsonism. *Proc. Natl. Acad. Sci. USA* **102**, 2174-2179.

Petit, J., Songnara, T., Piel, F., Delclous, M., Chen, F. G., Yu, Hasegawa, S., Hasele-Rad, S. et al. (2005). Wild-type PINK1 prevents basal and induced neuronal apoptosis, a protective effect abrogated by Parkinson disease-related mutations. *J. Biol. Chem.* **280**, 34025-34032.

Polymerssopilos, M. H. L., Gers, D. J., Ede, S. E., Dehejia, A., Dutra, A., Pike, B., Root, H., Rubenstein, J. B., Boyer, R. et al. (1997). Mutation in the alpha-synuclein gene identified in families with Parkinson’s disease. *Science* **276**, 2045-2047.

Pyle, A., Foltynie, T., Tiyangou, W., Lambert, C., Keers, S. M., Alcock, L. M.,
